Latest Cerus Corp (CERS) Headlines Research and
Post# of 44
Posted On: 03/12/2014 7:12:27 PM
Latest Cerus Corp (CERS) Headlines
Research and Markets: Smart Grid Round-Up, 2013 Research Report
Business Wire - Fri Feb 28, 2:48AM CST
Research and Markets (http://www.researchandmarkets.com/research/tv32p7/smart_grid) has announced the addition of the "Smart Grid Round-Up, 2013" report to their offering.
Cerus to Present at the Cowen and Company 34th Annual Health Care Conference, on March 4, 2014
Business Wire - Thu Feb 27, 7:30AM CST
Cerus Corporation (NASDAQ:CERS) announced today that William "Obi" Greenman, president and chief executive officer, is scheduled to present a corporate update at the Cowen and Company 34th Annual Health Care Conference at 11:20 AM ET on Tuesday, March 4, 2014.
Nasdaq stocks posting largest percentage decreases
AP - Wed Feb 26, 5:07PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
Cerus Shares Up -3.6% Since SmarTrend's Buy Recommendation (CERS)
Comtex SmarTrend(R) - Wed Feb 26, 9:23AM CST
SmarTrend identified an Uptrend for Cerus (NASDAQ:CERS) on February 11th, 2014 at $6.82. In approximately 2 weeks, Cerus has returned 3.58% as of today's recent price of $6.58.
Cerus Corporation Reports Fourth Quarter and Year-End 2013 Results
Business Wire - Tue Feb 25, 3:01PM CST
--2014 revenue guidance of $38-40 million; reflects potential negative impact to H1 sales from planned changes to distributor relationships.
Cerus to Release Fourth Quarter and Year End 2013 Results on February 25, 2014
Business Wire - Tue Feb 11, 7:30AM CST
Cerus Corporation (NASDAQ:CERS) announced today that its fourth quarter and year end results for 2013 will be released on Tuesday, February 25, 2014, after the close of the stock market. The company will host a conference call and webcast at 4:15 PM ET that afternoon, during which management will discuss the company's financial results and provide a general business overview and outlook.
Cerus (CERS) Soars: Stock Adds 6.5% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Feb 10, 8:39AM CST
Cerus Corporation was a big mover last session, as its shares rose nearly 7% on the day.
Can Cerus Corporation (CERS) Continue to Rise? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jan 09, 7:31AM CST
Can Cerus Corporation (CERS) Continue to Rise?
2 Biotech Stocks Under $10 Triggering Breakouts
at The Street - Wed Jan 08, 6:00AM CST
Keep these under-$10 biotech stock on your radar.
Cerus Appoints North American Sales Team Leadership
Business Wire - Wed Dec 11, 7:30AM CST
Cerus Corporation (NASDAQ: CERS) announced today the appointments of Kenneth Trader as vice president, sales, North America, and Scott Buker as senior director, North American market development. Both will join the company in January 2014. Mr. Trader will be responsible for sales operations in North America, including planning for anticipated product launches as well as establishing and building the sales team responsible for product adoption. Mr. Buker will be responsible for key launch activities and for management of national accounts in North America.
Cerus Submits Final Module in the Premarket Approval (PMA) Application Process for INTERCEPT Plasma
Business Wire - Wed Dec 04, 7:30AM CST
Cerus Corporation (NASDAQ: CERS) announced today that it has submitted the fourth and final module for its Premarket Approval (PMA) application to the U.S. Food and Drug Administration (FDA), for review of the INTERCEPT Blood System for plasma.
Iceland National Blood Bank Signs INTERCEPT Platelet and Plasma Agreement with Cerus
Business Wire - Wed Nov 20, 7:30AM CST
Cerus Corporation (NASDAQ:CERS) announced today that BloA deg bankinn, Iceland's national blood transfusion service at Landspitali University Hospital, has signed an agreement for the purchase of the INTERCEPT Blood System for platelets and plasma. BloA deg bankinn is the sole supplier of blood components in Iceland.
Cerus Announces Agreement with Health Canada for Regulatory Submission of the INTERCEPT Blood System for Platelets and Plasma
Business Wire - Wed Nov 06, 7:30AM CST
Cerus Corporation (NASDAQ: CERS) announced today that it has reached agreement with Health Canada regarding a regulatory submission for the INTERCEPT Blood System for platelets and plasma. Cerus plans to file with Health Canada for both products in the first half of 2014. Health Canada is the federal department in Canada that is responsible for review and authorization of drug, device and health products. Canada is supported by two blood services, Hema Quebec for the province of Quebec and Canadian Blood Services for the remainder of the country.
Shares of CERS Up 25.3% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Tue Nov 05, 9:45AM CST
SmarTrend identified an Uptrend for Cerus (NASDAQ:CERS) on July 15th, 2013 at $5.02. In approximately 4 months, Cerus has returned 25.28% as of today's recent price of $6.29.
2013 Report on the Worldwide Apheresis Market - with Forecasts to 2017
M2 - Fri Nov 01, 5:20AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7b5s5q/apheresis_market) has announced the addition of the "2013 Report on the Worldwide Apheresis Market - with Forecasts to 2017" report to their offering. Apheresis involves devices and disposables that leverage centrifugation and membrane separation/filtration technologies to separate blood components. Apheresis applications market studied in this report is segmented as plasmapheresis, plateletapheresis, erythrocytapheresis, leukapheresis, and other applications based on the various components collected in apheresis collection and therapeutic apheresis. The apheresis market is driven by the advantages of apheresis collection over the whole blood collection, huge demand for plasma in plasma fractionation and research for new applications of therapeutic apheresis. However, the cost of capital investment involved and the challenges in recruiting donors for apheresis collection are inhibiting the growth of this market. The global apheresis market was valued at $1,140.8 million in 2012 and is expected to reach $1,922.4 million by 2017 growing at a CAGR of 11.0% from 2012 to 2017. The application of therapeutic apheresis for pediatric treatment is an uncaptured market and represents a prospective opportunity in the future. Key Topics Covered: 1 Introduction 2 Executive Summary 3 Market Overview 4 Global Apheresis Market, By Procedure 5 Global Apheresis Market, By Product Type 6 Global Apheresis Market, By Technology 7 Global Apheresis Market, By Application 8 Geographic Analysis 8.1 Introduction 8.2 North America 8.3 Europe 8.4 Asia 8.5 Row (Rest Of The World) 9 Competitive Landscape 9.1 Introduction 9.2 Mergers & Acquisitions 9.3 Agreements, Partnerships, Collaborations & Joint Ventures 9.4 Products Launch 9.5 Expansions 9.6 Other Developments 9.7 Approvals 10 Company Profiles Companies Mentioned - Asahi Kasei Medical - B. Braun Melsungen - Cerus Corporation - Fenwal - Fresenius Medical Care Ag & Co - Haemonetics Corporation - Hemacare Corporation - Kaneka Corporation - Kawasumi Laboratories - Medica S.P.A - Nikkiso Co - Terumo Bct - Therakos For more information visit http://www.researchandmarkets.com/research/7b...sis_market
Cerus and the Swiss Red Cross Renew Commercial Contract with a Five-Year National Purchase Agreement for the INTERCEPT Blood System for Platelets
Business Wire - Thu Oct 31, 8:16AM CDT
--Demonstrates continued national commitment for use of INTERCEPT Blood System for pathogen inactivation of platelets in Switzerland
Cerus Corporation Reports Third Quarter 2013 Results
Business Wire - Tue Oct 29, 3:01PM CDT
--INTERCEPT platelet PMA initiated - first of three modules submitted in September.
Cerus Has Returned 36.5% Since SmarTrend Recommendation (CERS)
Comtex SmarTrend(R) - Tue Oct 29, 9:16AM CDT
SmarTrend identified an Uptrend for Cerus (NASDAQ:CERS) on July 15th, 2013 at $5.02. In approximately 4 months, Cerus has returned 36.45% as of today's recent price of $6.85.
Cerus Corporation names Daniel Swisher as new board chair
M2 - Tue Oct 22, 5:32AM CDT
Biomedical products company Cerus Corporation (NasdaqGM:CERS) reported on Monday the appointment of Daniel Swisher as chair of its board of directors.
Research and Markets: Smart Grid Round-Up, 2013 Research Report
Business Wire - Fri Feb 28, 2:48AM CST
Research and Markets (http://www.researchandmarkets.com/research/tv32p7/smart_grid) has announced the addition of the "Smart Grid Round-Up, 2013" report to their offering.
Cerus to Present at the Cowen and Company 34th Annual Health Care Conference, on March 4, 2014
Business Wire - Thu Feb 27, 7:30AM CST
Cerus Corporation (NASDAQ:CERS) announced today that William "Obi" Greenman, president and chief executive officer, is scheduled to present a corporate update at the Cowen and Company 34th Annual Health Care Conference at 11:20 AM ET on Tuesday, March 4, 2014.
Nasdaq stocks posting largest percentage decreases
AP - Wed Feb 26, 5:07PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
Cerus Shares Up -3.6% Since SmarTrend's Buy Recommendation (CERS)
Comtex SmarTrend(R) - Wed Feb 26, 9:23AM CST
SmarTrend identified an Uptrend for Cerus (NASDAQ:CERS) on February 11th, 2014 at $6.82. In approximately 2 weeks, Cerus has returned 3.58% as of today's recent price of $6.58.
Cerus Corporation Reports Fourth Quarter and Year-End 2013 Results
Business Wire - Tue Feb 25, 3:01PM CST
--2014 revenue guidance of $38-40 million; reflects potential negative impact to H1 sales from planned changes to distributor relationships.
Cerus to Release Fourth Quarter and Year End 2013 Results on February 25, 2014
Business Wire - Tue Feb 11, 7:30AM CST
Cerus Corporation (NASDAQ:CERS) announced today that its fourth quarter and year end results for 2013 will be released on Tuesday, February 25, 2014, after the close of the stock market. The company will host a conference call and webcast at 4:15 PM ET that afternoon, during which management will discuss the company's financial results and provide a general business overview and outlook.
Cerus (CERS) Soars: Stock Adds 6.5% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Feb 10, 8:39AM CST
Cerus Corporation was a big mover last session, as its shares rose nearly 7% on the day.
Can Cerus Corporation (CERS) Continue to Rise? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jan 09, 7:31AM CST
Can Cerus Corporation (CERS) Continue to Rise?
2 Biotech Stocks Under $10 Triggering Breakouts
at The Street - Wed Jan 08, 6:00AM CST
Keep these under-$10 biotech stock on your radar.
Cerus Appoints North American Sales Team Leadership
Business Wire - Wed Dec 11, 7:30AM CST
Cerus Corporation (NASDAQ: CERS) announced today the appointments of Kenneth Trader as vice president, sales, North America, and Scott Buker as senior director, North American market development. Both will join the company in January 2014. Mr. Trader will be responsible for sales operations in North America, including planning for anticipated product launches as well as establishing and building the sales team responsible for product adoption. Mr. Buker will be responsible for key launch activities and for management of national accounts in North America.
Cerus Submits Final Module in the Premarket Approval (PMA) Application Process for INTERCEPT Plasma
Business Wire - Wed Dec 04, 7:30AM CST
Cerus Corporation (NASDAQ: CERS) announced today that it has submitted the fourth and final module for its Premarket Approval (PMA) application to the U.S. Food and Drug Administration (FDA), for review of the INTERCEPT Blood System for plasma.
Iceland National Blood Bank Signs INTERCEPT Platelet and Plasma Agreement with Cerus
Business Wire - Wed Nov 20, 7:30AM CST
Cerus Corporation (NASDAQ:CERS) announced today that BloA deg bankinn, Iceland's national blood transfusion service at Landspitali University Hospital, has signed an agreement for the purchase of the INTERCEPT Blood System for platelets and plasma. BloA deg bankinn is the sole supplier of blood components in Iceland.
Cerus Announces Agreement with Health Canada for Regulatory Submission of the INTERCEPT Blood System for Platelets and Plasma
Business Wire - Wed Nov 06, 7:30AM CST
Cerus Corporation (NASDAQ: CERS) announced today that it has reached agreement with Health Canada regarding a regulatory submission for the INTERCEPT Blood System for platelets and plasma. Cerus plans to file with Health Canada for both products in the first half of 2014. Health Canada is the federal department in Canada that is responsible for review and authorization of drug, device and health products. Canada is supported by two blood services, Hema Quebec for the province of Quebec and Canadian Blood Services for the remainder of the country.
Shares of CERS Up 25.3% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Tue Nov 05, 9:45AM CST
SmarTrend identified an Uptrend for Cerus (NASDAQ:CERS) on July 15th, 2013 at $5.02. In approximately 4 months, Cerus has returned 25.28% as of today's recent price of $6.29.
2013 Report on the Worldwide Apheresis Market - with Forecasts to 2017
M2 - Fri Nov 01, 5:20AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7b5s5q/apheresis_market) has announced the addition of the "2013 Report on the Worldwide Apheresis Market - with Forecasts to 2017" report to their offering. Apheresis involves devices and disposables that leverage centrifugation and membrane separation/filtration technologies to separate blood components. Apheresis applications market studied in this report is segmented as plasmapheresis, plateletapheresis, erythrocytapheresis, leukapheresis, and other applications based on the various components collected in apheresis collection and therapeutic apheresis. The apheresis market is driven by the advantages of apheresis collection over the whole blood collection, huge demand for plasma in plasma fractionation and research for new applications of therapeutic apheresis. However, the cost of capital investment involved and the challenges in recruiting donors for apheresis collection are inhibiting the growth of this market. The global apheresis market was valued at $1,140.8 million in 2012 and is expected to reach $1,922.4 million by 2017 growing at a CAGR of 11.0% from 2012 to 2017. The application of therapeutic apheresis for pediatric treatment is an uncaptured market and represents a prospective opportunity in the future. Key Topics Covered: 1 Introduction 2 Executive Summary 3 Market Overview 4 Global Apheresis Market, By Procedure 5 Global Apheresis Market, By Product Type 6 Global Apheresis Market, By Technology 7 Global Apheresis Market, By Application 8 Geographic Analysis 8.1 Introduction 8.2 North America 8.3 Europe 8.4 Asia 8.5 Row (Rest Of The World) 9 Competitive Landscape 9.1 Introduction 9.2 Mergers & Acquisitions 9.3 Agreements, Partnerships, Collaborations & Joint Ventures 9.4 Products Launch 9.5 Expansions 9.6 Other Developments 9.7 Approvals 10 Company Profiles Companies Mentioned - Asahi Kasei Medical - B. Braun Melsungen - Cerus Corporation - Fenwal - Fresenius Medical Care Ag & Co - Haemonetics Corporation - Hemacare Corporation - Kaneka Corporation - Kawasumi Laboratories - Medica S.P.A - Nikkiso Co - Terumo Bct - Therakos For more information visit http://www.researchandmarkets.com/research/7b...sis_market
Cerus and the Swiss Red Cross Renew Commercial Contract with a Five-Year National Purchase Agreement for the INTERCEPT Blood System for Platelets
Business Wire - Thu Oct 31, 8:16AM CDT
--Demonstrates continued national commitment for use of INTERCEPT Blood System for pathogen inactivation of platelets in Switzerland
Cerus Corporation Reports Third Quarter 2013 Results
Business Wire - Tue Oct 29, 3:01PM CDT
--INTERCEPT platelet PMA initiated - first of three modules submitted in September.
Cerus Has Returned 36.5% Since SmarTrend Recommendation (CERS)
Comtex SmarTrend(R) - Tue Oct 29, 9:16AM CDT
SmarTrend identified an Uptrend for Cerus (NASDAQ:CERS) on July 15th, 2013 at $5.02. In approximately 4 months, Cerus has returned 36.45% as of today's recent price of $6.85.
Cerus Corporation names Daniel Swisher as new board chair
M2 - Tue Oct 22, 5:32AM CDT
Biomedical products company Cerus Corporation (NasdaqGM:CERS) reported on Monday the appointment of Daniel Swisher as chair of its board of directors.
(0)
(0)Cerus Corporation (CERS) Stock Research Links
Scroll down for more posts ▼